A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer

BACKGROUND: Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) are mainly used in the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC), but a comprehensive clinical evaluation of ALK-TKIs is lacking. Hence, a comparison of ALK-TKIs for first-line treatment of ALK-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wan-Qing, Xu, Tao, Zhang, Jing-Jing, Wang, Yong, Wang, Yao, Zhang, Wei, Zhu, Jian-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183550/
https://www.ncbi.nlm.nih.gov/pubmed/37197536
http://dx.doi.org/10.21037/jtd-23-380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183550/
https://www.ncbi.nlm.nih.gov/pubmed/37197536
http://dx.doi.org/10.21037/jtd-23-380

Ejemplares similares